RSU vesting gives Precigen (PGEN) director 71839 new common shares

Rhea-AI Filing Summary

PRECIGEN, INC. director Jeffrey B. Kindler received common stock through the vesting of previously granted restricted stock units. On March 13, 2026, 71839 RSUs vested in full, converting into 71839 shares of common stock at no exercise price. Following this compensation-related transaction, he directly holds 202100 shares of Precigen common stock, with no reported open-market purchases or sales and no remaining derivative holdings in this filing.

Insider Trade Summary

71,839 shares exercised/converted

Mixed 2 txns

Insider KINDLER JEFFREY B

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	71,839	$0.00	--
Exercise	Common Stock	71,839	$0.00	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Common Stock — 202,100 shares (Direct)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. The RSUs vested in full on March 13, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KINDLER JEFFREY B

(Last) (First) (Middle)

20374 SENECA MEADOWS PARKWAY

(Street)

GERMANTOWN MD 20876

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PRECIGEN, INC. [ PGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		M		71,839	A	(1)	202,100	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/13/2026		M			71,839	(2)	(2)	Common Stock	71,839	$0	0	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

2. The RSUs vested in full on March 13, 2026.

	/s/ Jeffrey B. Kindler, by Donald P. Lehr, as attorney-in-fact	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Precigen (PGEN) disclose for Jeffrey B. Kindler?

Precigen reported that director Jeffrey B. Kindler acquired common shares through restricted stock unit vesting. On March 13, 2026, 71839 RSUs converted into 71839 shares of common stock as part of his equity compensation, with no open-market buying or selling reported.

How many Precigen (PGEN) restricted stock units vested for the director?

A total of 71839 restricted stock units vested for the director. Each RSU represented a contingent right to receive one share of Precigen common stock, and all vested in full on March 13, 2026, resulting in the same number of new common shares.

How many Precigen (PGEN) shares does Jeffrey B. Kindler hold after this Form 4?

After the RSU vesting and conversion, Jeffrey B. Kindler directly holds 202100 shares of Precigen common stock. This reflects the addition of 71839 shares from vested RSUs, as reported in the Form 4, with no remaining derivative securities listed in this filing.

Did the Precigen (PGEN) director sell any shares in this Form 4 filing?

The Form 4 shows no open-market sales by the director. The only reported activity is the exercise and conversion of 71839 restricted stock units into an equal number of common shares at a price of 0.0000 per share, typical for equity compensation vesting.

What does the RSU vesting mean for Precigen (PGEN) director compensation?

The RSU vesting represents the delivery of equity compensation previously granted to the director. On March 13, 2026, 71839 RSUs vested in full, converting into 71839 common shares at no cost, aligning his compensation partly with Precigen’s share performance through stock ownership.